Four Problems with the DNA Database
By Sharon Fernandes,
Times of India
| 08. 02. 2015
Untitled Document
India's Human DNA Profiling Bill 2015 proposes to set up a national DNA database of criminals that will include rapists, murderers and kidnappers. But the proposed draft is being criticized on several grounds — from being insensitive to privacy issues to allowing intrusive modes of sample collection.
The draft has been drawn up by the Department of Biotechnology in association with an autonomous institution, the Centre for DNA Fingerprinting and Diagnostics (CDFD) and has been in the works for 12 years. But international activist groups monitoring developments in genetic technologies like GeneWatch UK, Council for Responsible Genetics, USA and online collectives like The Forensic Genetics Policy Initiative (FGPI) say it doesn't have enough safeguards built into it.
Too large and sweeping
The DNA databank, as visualized in the draft bill, will have six categories, ranging from suspects to missing persons (see box). The offenders' index in the final bill may even encompass minor crimes such as the MV (Motor Vehicles) Act offences.
"Making the database too big and poorly regulated will not help solve more crimes," says Helen...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...